MorphoSys AG (NASDAQ:MOR – Get Free Report) has received an average recommendation of “Hold” from the nine brokerages that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $14.00.
Several research analysts recently weighed in on MOR shares. JPMorgan Chase & Co. raised MorphoSys from an “underweight” rating to an “overweight” rating and increased their target price for the stock from $3.30 to $10.00 in a research report on Friday, June 16th. UBS Group initiated coverage on MorphoSys in a research note on Wednesday, May 31st. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft upgraded MorphoSys from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Wells Fargo & Company started coverage on MorphoSys in a report on Friday, June 16th. They set an “overweight” rating and a $17.00 price target on the stock.
Institutional Inflows and Outflows
MorphoSys Stock Performance
Shares of NASDAQ:MOR opened at $7.54 on Friday. The business’s fifty day moving average price is $7.71 and its two-hundred day moving average price is $6.23. The company has a current ratio of 3.57, a quick ratio of 3.27 and a debt-to-equity ratio of 7.56. MorphoSys has a one year low of $3.17 and a one year high of $8.67.
MorphoSys (NASDAQ:MOR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.59) earnings per share (EPS) for the quarter. MorphoSys had a return on equity of 154.85% and a net margin of 27.67%. The business had revenue of $57.91 million for the quarter. Sell-side analysts forecast that MorphoSys will post -1.94 EPS for the current fiscal year.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- Five stocks we like better than MorphoSys
- High Dividend REITs: Are They an Ideal Way to Diversify?
- These 3 Wood Stocks are about to go on Discount
- What Investors Need to Know to Beat the Market
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- How to Invest in Biotech Stocks
- 3 Stocks Awaiting Winter Winds of Opportunity
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.